Cargando…
VEGF Blockade Decreases Tumor Uptake of Systemic Oncolytic Herpes Virus but Enhances Therapeutic Efficacy When Given After Virotherapy
Effective therapies for metastatic sarcomas remain elusive. Oncolytic viruses have shown promise as anticancer agents, but their access to metastatic sites following systemic delivery is low. Because systemic delivery of small molecule chemotherapy is enhanced by prior treatment with anti-angiogenic...
Autores principales: | Eshun, Francis K., Currier, Mark A., Gillespie, Rebecca A., Fitzpatrick, Jillian L., Baird, William H., Cripe, Timothy P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900405/ https://www.ncbi.nlm.nih.gov/pubmed/20508601 http://dx.doi.org/10.1038/gt.2010.82 |
Ejemplares similares
-
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chen, Chun-Yu, et al.
Publicado: (2017) -
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
por: Denton, Nicholas L., et al.
Publicado: (2018) -
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
por: Mamola, Joseph A., et al.
Publicado: (2023) -
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation
por: Currier, Mark A., et al.
Publicado: (2017) -
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
por: Denton, Nicholas L., et al.
Publicado: (2016)